Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following He...(products that may be regarded as safer m...),Health

Date:4/15/2008

products that may be regarded as safer, more effective, easier to use or less expensive, that results or trends observed in one clinical study will be reproduced in subsequent studies, that third parties on whom we depend will behave as anticipated, that necessary regulatory approvals will be obtained. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development, testing and marketing of therapeutic hypothermia devices and whether our efforts to launch new devices and systems will be successful or completed within the time frames contemplated, risks and uncertainties that are inherent in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Privacy Policy, please visit http://www.cardiumthx.com.

Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium

Therapeutics, Inc. Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are trademarks of

Tissue Repair Company.

InnerCool Therapies(R), InnerCool(R), Celsius Control System(TM), RapidBlue(TM), CoolBlue(TM) and Accutrol(TM) are trademarks of I
'/>"/>

SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine technology :

1. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
2. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
7. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
8. Vital Therapies Announces Presentation of ELAD(R) Artificial Liver Data at American Association for the Study of Liver Diseases 2007 Annual Meeting
9. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
10. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
11. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias